Definium reports full-year 2025 results with $411.6M cash and three 2026 Phase 3 readouts on track

Definium Therapeutics, Inc. (DFTX) — In its first annual report under the new name, Definium Therapeutics reported $411.6 million in cash and investments as of year-end 2025, a runway it said funds operations into 2028.

The company confirmed its Emerge Phase 3 MDD trial is fully enrolled (topline expected late Q2 2026), Voyage (GAD) is roughly 80% enrolled (early Q3 2026), and Panorama (GAD) enrollment is on track for a 2H 2026 readout. Management framed 2026 as a pivotal year with three Phase 3 topline readouts for its optimized-LSD lead DT120.

Source: finance.yahoo.com

For the rest of that week's sector news, read our week in review.